Online Only Articles

NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia

Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany;European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany
HELIOS Medical Clinic Berlin-Buch, Clinic for Hematology, Oncology, Tumor Immunology and Palliative Care, Berlin
HELIOS Medical Clinic Berlin-Buch, Clinic for Hematology, Oncology, Tumor Immunology and Palliative Care, Berlin
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
Department of Pediatric Oncology, Hematology and Immunology, University of Heidelberg, Heidelberg, Germany;Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin
Department of Pediatrics, Division of Oncology and Hematology, Charité – University Medical Center Berlin;German Cancer Consortium (DKTK), and German Cancer Research Center (DKFZ), Heidelberg, Germany
Vol. 102 No. 7 (2017): July, 2017 https://doi.org/10.3324/haematol.2016.157792